Influence of polymorphisms in MTHFR 677 C→→T, TYMS 3R→→2R and MTR 2756 A→→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC

Author： Cui Lian-Hua   Yu Zhuang   Zhang Ting-Ting   Shin Min-Ho   Kim Hee-Nam   Choi Jin-Su  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.12, Iss.6, 2011-06, pp. : 797-808

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacogenomics of platinum-based chemotherapy in NSCLC

By Hildebrandt Michelle AT   Gu Jian   Wu Xifeng  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 7, 2009-07 ,pp. : 745-755

Informa Healthcare

Access to resources Recommend Favorite

Gemcitabine + vinorelbine: superior to platinum-based regimens in NSCLC?

By  

Inpharma, Vol. 1, Iss. 1308, 2001-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis

By Kurzawski Mateusz   Pawlik Andrzej   Safranow Krzysztof   Herczynska Magdalena   Drozdzik Marek  

Pharmacogenomics, Vol. 8, Iss. 11, 2007-11 ,pp. : 1551-1559

Future Medicine

Access to resources Recommend Favorite

Polymorphisms: prognostic factors in advanced NSCLC?

By  

Inpharma, Vol. 1, Iss. 1454, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Platinum- and non-platinum-based regimens compared in NSCLC

By  

Inpharma, Vol. 1, Iss. 1288, 2001-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite